Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases

J Med Virol. 2021 Feb;93(2):689-691. doi: 10.1002/jmv.26488. Epub 2020 Sep 29.

Authors

Nicolas Dauby¹, Serge Van Praet², Charlotte Vanhomwegen³, Ioannis Veliziotis³, Deborah Konopnicki¹, Alain Roman³

Affiliations

¹ Department of infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
² Department of Pharmacy, CHU Saint-Pierre, Brussels, Belgium.
³ Intensive Care Unit, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.

PMID: 32886358
DOI: 10.1002/jmv.26488

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Amides / adverse effects
Amides / therapeutic use*
COVID-19 / physiopathology*
COVID-19 / therapy*
Critical Illness / therapy
Female
Humans
Male
Middle Aged
Pyrazines / adverse effects
Pyrazines / therapeutic use*

Substances

Amides
Pyrazines
favipiravir